Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma

NCT01534585 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG: Icotinib
RADIATION: intensity-modulated radiotherapy
DRUG: Paclitaxel and Cisplatin
OTHER: Quality of life
GENETIC: Epidermal growth factor receptor status

Sponsor

Taizhou Hospital